XNAS · Healthcare · Biotechnology
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-13 | Q2 2026 | -2.32 | -2.34 | -0.86% | $0 | ❌ Miss | +0.00% | +2.21% | — |
| 2026-05-14 | Q1 2026 | -1.43 | -2.15 | -50.35% | $0 | ❌ Miss | -0.41% | -4.81% | -20.63% |
| 2026-03-19 |
| Q4 2025 |
| -2.45 |
| -2.11 |
| +13.88% |
| $0 |
| ✅ Beat |
| -0.26% |
| +1.42% |
| +36.01% |
| 2025-11-14 | Q3 2025 | -2.21 | -2.28 | -3.17% | $0 | ❌ Miss | — | — | — |
| 2025-08-13 | Q2 2025 | -2.73 | -1.85 | +32.23% | $1.3M | ✅ Beat | -0.47% | +3.56% | +16.76% |
| 2025-03-17 | Q4 2024 | — | -3.09 | — | $100,000 | — | +0.43% | +5.60% | -17.72% |
| 2024-11-14 | Q3 2024 | -3.38 | -2.84 | +15.98% | $0 | ✅ Beat | -3.49% | -2.44% | +1.60% |
| 2024-08-13 | Q2 2024 | -1.47 | 125.48 | +8636.05% | $100,000 | ✅ Beat | -0.09% | +14.25% | +33.45% |
Showing last 8 quarters.